2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

4153 Successful generation of NK and NKT-like cells from AML patient PBMCs for autologous bone marrow-homing cellular immunotherapy

Evan C. Chen, MD, Daniel J DeAngelo, MD, PhD2, Mariia Vorobeva, BS3, Madeleine Rostad, BS4, Frank Borriello, MD PhD5, James Lederer6
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Brigham & Women's Hospital, Boston, Massachusetts, United States
4 Brigham & Women's Hospital, Boston, Massachusetts, United States
5 Alloplex Biotherapeutics, Woburn, Massachusetts, United States
6 Brigham & Women's Hospital, Boston, Massachusetts, United States

Introduction: We previously generated therapeutic NK and NKT-like cells with anti-cancer activity from peripheral blood mononuclear cells (PBMCs) of patients with advanced colorectal, kidney, and melanoma patients in a Phase 1 clinical trial (NCT05237206).  This process used an immune cell training platform consisting of SK-MEL2 cells modified by a proprietary set of immunomodulatory receptors, ligands, and cytokines (Alloplex Biotherapeutics). The “trained” NK and NKT-like cells acquire potent anti-tumor cytolytic activity, antigen presenting cell (APC) capacity, and bone marrow homing activity. Results of this Phase 1 trial showed excellent safety and promising efficacy with NK/NKT-like cell therapy. Treated patients also showed a shift from circulating suppressive-type myeloid cells to normal myeloid cell types, suggesting restoration of immunologic homeostasis. Here, we tested the feasibility of generating therapeutic NK and NKT-like cells for patients with acute myeloid leukemia (AML).

Methods: Cryopreserved PBMCs were obtained from 13 AML patients with a median age of 73 years (range 56-82), 62% male sex, and median 7% peripheral blasts (range 0-80%), with mutations in NPM1 (n=3), TP53 (n=3), IDH2 (n=3), IDH1 (n=1), FLT3-TKD (n=1), FLT3-ITD (n=1), and JAK2 (n=1).  As a control, PBMCs were obtained from 7 normal healthy volunteers (NHVs) with a median age of 63 years (range 54-75) and 57 % male sex. PBMCs were thawed and incubated with SK-MEL2 tumor cells expressing an array of immunomodulatory factors as a blood immune cell training reagent. Successful immune cell training was reflected by activation cluster formation at 5 days and by effective expansion. After 14 days of co-incubation, the “trained” PBMC-derived immune cells were cryopreserved. Single-cell phenotyping of these cells was performed by CyTOF using a 46-marker antibody panel and analyzed by unbiased clustering (FlowSom) and visualization methods (UMAP and PHATE) in OMIQ. Comparative tumor cytolysis assays were done by incubating trained immune cels with GFP-labeled K562 target cells at effector-to-target-cell ratios of 2:1, 4:1, and 8:1.  The anti-proliferative effect of cytarabine, decitabine, and azacitidine on immune cell training was also evaluated.

Results: NK/NKT-like effector cells were successfully “trained” from cryopreserved PBMCs from 11 of 13 (85%) AML patients. The 2 unsuccessful samples were associated with low recovery of cryopreserved PBMCs. Analysis of CyTOF staining showed that the expanded cells from 11 AML and 7 NHV PBMCs had highly similar populations of NK and NKT-like cells that expressed APC (HLA-DR, CD86), cytolysis (granzyme B, granulysin, NKG2D), and bone marrow homing (CXCR4, CXCR3) markers. Analysis of CyTOF staining data by PHATE, which organizes staining data into developmental trajectories of cells, showed minimal phenotypic differences between NK/NKT-like cells developed from AML patients versus NHVs. Comparison of tumor cell cytolysis showed strong cytolytic activity at a 2:1 effector:target ratio with no statistical differences in potency between NK/NKT-like cells derived from AML and NHV PBMCs.  Finally, PBMCs from AML patients were more resistant to the anti-proliferative activity of cytarabine, azacitidine, and decitabine than PBMCs from NHVs. Importantly, NK/NKT-like cells successfully expanded during immune cell training even when exposed to azacitidine, decitabine, or cytarabine.

Conclusions: PBMCs from 11 of 13 AML patients with diverse mutations and disease burden showed effective generation of activated NK and NKT-like cells upon immune cell training with modified SK-MEL2 cells. Trained AML NK/NKT-like cells showed high expression levels of APC and bone marrow homing markers, exhibited high anti-tumor cytolysis in vitro, and was resistant to exposure to cytarabine and hypomethylating agents.  Clinical translation of this novel NK/NKT-like cell therapy for patients with AML and high-risk MDS is underway.

Evan C. Chen, MD: Syndax - Research Funding; Arcellx - Research Funding; Takeda - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony)